The recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the phase III OnTarget trial indicate that crofelemer (Mytesi, Fulyzaq) achieved statistical significance in this subgroup.
Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.
